Eplerenone NEW
| Price | $44 | $63 | $127 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Eplerenone | CAS No.: 107724-20-9 |
| Purity: ≥98% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Eplerenone |
| Description | Eplerenone (CGP 30083) is an aldosterone receptor antagonist and potassium-sparing diuretic used in the therapy of hypertension. Eplerenone therapy has been associated with transient elevations in serum aminotransferase levels, but has yet to be linked to cases of clinically apparent drug induced liver disease. |
| In vitro | Eplerenone increases total vascular and luminal areas in swine without affecting the endothelial area. In canine models, it significantly reduces left ventricular end-diastolic wall stress. Eplerenone attenuates the rise in pulse pressure due to aldosterone (Aldo) in rats, normalizing the wall stress curve, mean cross-sectional area, and EIIIA fibronectin levels in Aldo-salt hypertensive rats. The compound upregulates diminished endothelial nitric oxide synthase mRNA in Dahl salt-sensitive hypertensive (DS) rats, markedly improving glomerulosclerosis and proteinuria. In mice, daily administration of 200 mg/kg of Eplerenone significantly lowers systolic and diastolic blood pressures compared to controls and increases serum phosphatase activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.1 mg/mL (10 mM) |
| Keywords | cardiovascular (CV) | aldosterone | atherosclerosis | CGP-30083 | specific | hypertension | SC 66110 | SC66110 | inhibit | Eplerenone | Inhibitor | CGP30083 | Endogenous Metabolite | MRA | chronic systolic heart failure (HF) | Mineralocorticoid Receptor |
| Inhibitors Related | Nimodipine | Hydrocortisone | Mifepristone | Prednisolone acetate | Cortisone | Dexamethasone acetate | Dexamethasone Phosphate disodium | Prednisone acetate | Desonide | Corticosterone |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $44.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2024-10-11 | |
| $980.00/1ton |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-15 | |
| $0.00/1kg |
VIP1Y
|
Hangzhou Hyper Chemicals Limited
|
2024-06-13 | |
| $9.00/1g |
VIP1Y
|
Hebei Kangcang new material Technology Co., LTD
|
2024-03-22 | |
| $10.00/1kg |
Nantong Guangyuan Chemicl Co,Ltd
|
2023-11-01 | ||
| $0.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-10-07 | |
| $301.00/10g |
VIP3Y
|
Hebei Dangtong Import and export Co LTD
|
2023-09-15 | |
| $0.00/1KG |
VIP2Y
|
Wuhan Haorong Biotechnology Co.,Ltd
|
2023-07-27 | |
| $150.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-05-25 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY